{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:57:43Z","timestamp":1792735063198,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.msard.2025.106723","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T06:57:11Z","timestamp":1756969031000},"page":"106723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Breaking the assumption: Disease-modifying therapy efficacy and relapse severity in relapsing-remitting multiple sclerosis"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4129-9817","authenticated-orcid":false,"given":"Luis A.","family":"Rodriguez de Antonio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Garc\u00eda-Casta\u00f1\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Gonz\u00e1lez-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Oreja-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.msard.2025.106723_bib0001","first-page":"1746","article-title":"Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy","volume":"25","author":"Achiron","year":"2019","journal-title":"MultScler"},{"key":"10.1016\/j.msard.2025.106723_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102769","article-title":"Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-a systematic review and network meta-analysis","volume":"49","author":"Bartosik-Psujek","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106723_bib0020","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fneur.2018.01150","article-title":"The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses","volume":"9","author":"Claflin","year":"2019","journal-title":"Front. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2025.106723_bib0028","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/0022-510X(93)90215-K","article-title":"The Extended Disability Status Scale (EDSS) as a predictor of impairments of functional activities of daily living in multiple sclerosis","volume":"115","author":"Cohen","year":"1993","journal-title":"J. Neurol. Sci."},{"issue":"11","key":"10.1016\/j.msard.2025.106723_bib0027","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S1474-4422(19)30238-8","article-title":"Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial","volume":"18","author":"Cohen","year":"2019","journal-title":"Lancet Neurol."},{"issue":"9700","key":"10.1016\/j.msard.2025.106723_bib0009","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(09)61259-9","article-title":"Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Comi","year":"2009","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.msard.2025.106723_bib0006","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1177\/1352458518800815","article-title":"Age is a critical determinant in recovery from multiple sclerosis relapses","volume":"25","author":"Conway","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106723_bib0023","first-page":"80p07","article-title":"Relapse is associated with residual deficits in relapsing-remitting multiple sclerosis: analysis of FREEDOMS data (P07.118)","author":"Cutter","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2025.106723_bib0024","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.msard.2025.106723_bib0025","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2025.106723_bib0022","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.msard.2016.08.002","article-title":"Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up","volume":"10","author":"Hersh","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"11","key":"10.1016\/j.msard.2025.106723_bib0010","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1177\/1352458514528762","article-title":"MSBase Study Group. Risk of relapse phenotype recurrence in multiple sclerosis","volume":"20","author":"Kalincik","year":"2014","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106723_bib0029","first-page":"e653","article-title":"Relapse recovery: the forgotten variable in multiplesclerosisclinicaltrials","volume":"7","author":"Kantarci","year":"2019","journal-title":"Neurol. NeuroimmunolNeuroinflamm."},{"issue":"9585","key":"10.1016\/j.msard.2025.106723_bib0008","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0140-6736(07)61194-5","article-title":"Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study","volume":"370","author":"Kappos","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.msard.2025.106723_bib0026","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1001\/jamaneurol.2021.0405","article-title":"Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial","volume":"78","author":"Kappos","year":"2021","journal-title":"JAMA Neurol."},{"issue":"0","key":"10.1016\/j.msard.2025.106723_bib0003","article-title":"Relapse recovery in relapsing\u2013remitting multiple sclerosis: an analysis of the CombiRx dataset","volume":"0","author":"Koch","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2025.106723_bib0018","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2025.106723_bib0019","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00415-020-10154-5","article-title":"SMILE: a predictive model for Scoring the severity of relapses in MultIplescLErosis","volume":"268","author":"Lejeune","year":"2021","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2025.106723_bib0004","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1177\/1352458507084650","article-title":"Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study","volume":"14","author":"Leone","year":"2008","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106723_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.ypmed.2024.108180","article-title":"Comparative effectiveness of high-efficacy and moderate efficacy disease-modifying agents in reducing the annualized relapse rates among multiple sclerosis patients in the United States","volume":"190","author":"Li","year":"2025","journal-title":"Prev. Med."},{"key":"10.1016\/j.msard.2025.106723_bib0015","series-title":"Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis","article-title":"Assessment of relapse activity in the CombiRx randomised clinical trial","author":"Lublin","year":"2012"},{"issue":"6","key":"10.1016\/j.msard.2025.106723_bib0012","first-page":"705","article-title":"Belachew S. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS","volume":"3","author":"Lublin","year":"2014","journal-title":"MultSclerRelatDisord"},{"issue":"9","key":"10.1016\/j.msard.2025.106723_bib0002","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106723_bib0030","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2174\/1874205X01105010075","article-title":"Predictors of attack severity and duration in multiple sclerosis: a prospective study","volume":"5","author":"Naldi","year":"2011","journal-title":"Open Neurol. J."},{"issue":"10","key":"10.1016\/j.msard.2025.106723_bib0013","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1007\/s00415-013-6979-y","article-title":"Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use","volume":"260","author":"O'Connor","year":"2013","journal-title":"J. Neurol."},{"issue":"17","key":"10.1016\/j.msard.2025.106723_bib0014","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1212\/WNL.0000000000005347","article-title":"Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2025.106723_bib0017","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.nrl.2023.06.005","article-title":"Treatment adherence in patients with multiple sclerosis: risk factors","volume":"40","author":"Rodr\u00edguez de Antonio","year":"2025","journal-title":"Neurologia (Engl. Ed)"},{"issue":"2","key":"10.1016\/j.msard.2025.106723_bib0005","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1177\/1352458516643392","article-title":"Contribution of different relapse phenotypes to disability in multiple sclerosis","volume":"23","author":"Stewart","year":"2017","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2025.106723_bib0016","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"issue":"6","key":"10.1016\/j.msard.2025.106723_bib0007","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/01.wnl.0000237354.10144.ec","article-title":"Baseline MRI predicts future attacks and disability in clinically isolated syndromes","volume":"67","author":"Tintor\u00e9","year":"2006","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825004651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:26:14Z","timestamp":1784345174000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825004651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":30,"alternative-id":["S2211034825004651"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106723","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Breaking the assumption: Disease-modifying therapy efficacy and relapse severity in relapsing-remitting multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106723"}}